Introduction
Stem cell apheresis products, unlike conventional blood products, cross international borders. Transplant centers receive stem cell products from a multitude of cell collection facilities, often from facilities that are not subject to the same laws as the transplantation center. 1 Thus, 430% of volunteer donor stem cell transplants worldwide and 44% in the United States of America, originate from abroad. 2 The fear of donor-derived communicable diseases looms large, so that several countries require repeat infectious disease markers (IDM) testing in the receiving country, irrespective of the product's origin. By contrast, the receiving end has few possibilities to detect a donor mix-up, that is, the fact that cells from the wrong donor contained in the delivered product would go unrecognized even though this error would be fatal. We know from conventional blood products that the latter risk outweighs the former by several orders of magnitude. 3 Currently, most transplant center physicians infuse the cell product based solely on clear-script identification of donor and recipient from label and product information, sometimes supplemented by ABO and Rh typing on a companion tube of whole blood, in other words, without any biological identification of the proper product. Some transplant centers perform ABD testing on the apheresis product with the tube test technology. Results are of questionable quality because of the unfavorable ratio between hematocrit (2-3%) and leukocyte count (200-400 g/mL) of a stem cell apheresis product. Moreover, ABD testing is poorly discriminating, as the most common blood types A Rh þ and O Rh þ are each shared by 435% of the Caucasian population.
Even though transfusion of the wrong stem cell product has not been reported in the literature, the overall likelihood of human error and reports on error frequency associated with cord blood units 4 and red cell concentrates 3 make it likely that it can occur, and suggest that an additional level of ascertainment of donor identity in addition to those taken by the apheresis facility might increase the safety of stem cell products. We reasoned that transplant centers might benefit from a point-of-care product identification assay on the product itself, immediately before transplantation. Such a test must rely on donor information available to the transplant center, and must offer a high degree of discrimination. Extended blood typing fulfils these criteria. Assays were selected based on available technology. Pre-analytical protocols were established to accommodate the very low hematocrit of peripheral blood stem/progenitor cell apheresis products and the skewed frequency of erythrocytes to leukocytes. The tests can be performed within 6 (lateral flow cards) to 12 (gel agglutination cards) minutes, with 1 min hands-on time for either protocol, on the contents of a 10-cm (4 00 ) tube segment from the stem cell bag or from a quality control sample collected in the transplant center, that is, without compromising the integrity of the product.
Materials and methods

Stem cell apheresis samples
Leftover material from 193 unselected quality control samples from matched-unrelated G-CSF mobilized stem cell apheresis products collected at our institution between January and July of 2010 was used in an anonymized fashion with permission of the local Institutional review board (IRB). Until analysis, samples were stored at room temperature (18-22 1C) without agitation. At the time of analysis, product samples were 12-60 h old. Hematocrit was 2.4 ± 0.03 g/dL (mean ± s.e.m.; range 0.9-9.2 g/dL) and leukocyte count was 241 ± 2.4/nL (mean ± s.e.m.).
Blood typing using lateral flow technology Blood group typing by lateral flow (MDmulticard ABO-DRh subgroups-K for patients, Medion Grifols Diagnostics, Du¨dingen, Switzerland) is a novel technology and is briefly explained here. 5 Analysis and interpretation are simple, the assay takes about 5 min, and is completely independent from any kind of equipment. Cards consist of a medially located sample application field, bilaterally to which are arranged a total of 10 rocket-shaped areas impregnated with monoclonal antisera against A, B, D (two spots with a mix of two different antisera each), K, C, C w , c, E (mix of two antisera) and e (mix of two antisera), as well as circular positive control (pan-agglutinating antiserum) and negative control (vehicle only) spots on either side of the sample application field. For a list of antisera see Table 1 . Located bilaterally at the extremes of the card are wicks collecting the liquids, which are applied to the application field (cartoon: Figure 1 , photograph: Figure 2a ). As erythrocytes flow over the immobilized antisera, those erythrocytes expressing the corresponding Ag are retained. Erythrocyte suspension in proprietary Diluent F is applied to the sample application field, and allowed to diffuse laterally into the test card for 420 s. Unbound erythrocytes are subsequently eluted with Diluent F. Lateral flow cards are read visually between 5 min and 24 h thereafter. They are scored as negative or positive for the respective parameter based on whether erythrocytes are retained or not. Positive reactions can be further semiquantitatively graded from weakly to strongly reactive, but this distinction was not made for the purpose of these studies.
Blood typing using gel column centrifugation technology Gel column centrifugation technology has been used in immunohematology diagnostics since many years. 6 Briefly, a dilute erythrocyte suspension is pipetted into the reaction chambers above the wells of gel cards containing, in each well, specific Ab (combinations) against individual blood group Ags. If the Ab meets its cognate Ag on the erythrocytes, erythrocytes are agglutinated. During centrifugation in centrifuges specific for the gel card brand, agglutinates are retained on top of or dispersed throughout the gel column, while Ag-negative, non-agglutinated erythrocytes are forced to the bottom of the gel column, that is, cells are scored negative or positive depending on the position of the erythrocyte pellet in the column. Negative control columns serve to exclude nonspecific retention and thus false-positive readings. Reaction strength is also routinely considered, but as with the lateral flow card it was ignored here. Gel card assays were from DiaMed (DiaMed-ID Micro Typing System Diaclon ABO/ Rh for patients and Diaclon Rh subgroups K, DiaMed Deutschland, Munich, Germany) and Grifols (DG Gel ABO/Rh and DG Gel Rh þ Kell, Diagnostic Grifols, Barcelona, Spain).
Blood grouping assay adapted for PBSC apheresis samples Alternative blood typing protocols were developed, because, with their very low hematocrits, the manufacturerrecommended protocols for peripheral blood were not suitable for direct testing of stem cell apheresis products (see Results). Starting with 1 mL of stem cell apheresis product, erythrocytes were enriched by centrifugation in an Eppendorf tube, using a standard microcentrifuge (800 Â g) for 1 min. A 35 mL of erythrocyte-rich sediment was aspirated from the bottom of the tube and suspended in two drops (100 mL) of Diluent F (lateral flow cards), or 10 mL of erythrocyte sediment was suspended in 150 mL IDDiluent 2 (gel cards).
Blood group Ags A, B, D, K, C, C w , c, E and e were determined, using commercially available lateral flow cards. The suspension of erythrocyte sediment in Diluent F was applied to the lateral flow card, followed by elution 30 s later with six drops (300 mL) of Diluent F, as illustrated in the cartoon in Figure 1 . Results were read after 5-30 min by Table 1 Sera impregnated on the lateral flow card MDmulticard ABO-D-Rh subgroups-K for patients
Antigen
Antibody Clone
MS-110
Apheresis product ID by extended blood typing C Cummerow et al two independent analysts, and additionally documented with a standard digital camera (Figure 2a) .
Alternatively, into each of the 12 wells (pre-filled with Abs against A, B, AB, D, CDE, C, c, E, e and K, as well as two negative controls) of the two DiaMed gel cards, 10 mL of erythrocyte suspension in IDDiluent 2 were given, and gel cards were immediately centrifuged for 10 minutes. Results were read immediately by two independent analysts, and additionally documented with a standard digital camera (Figure 2b) .
As a reference method, a fully automated microtiterplate-based agglutination assay was performed on a blood sample collected at the time of the apheresis analyzed on the Olympus PK-7300 (Olympus Deutschland GmbH, Hamburg, Germany); those data were obtained by data bank extraction without de-anonymizing the donors.
Sample size estimation, evaluation and statistics Analysis of apheresis products with blood group assays for the purpose of donor identity confirmation constitutes 'off-label' use of the in vitro diagnostic device (IVD); stringent 'list A' guidelines (CTS Annex II, EU Directive 98/79/EC) were therefore not applied. A sample size of 100 was chosen to test robustness of the modified protocol with the lateral flow blood typing assay. A smaller cohort was tested with the gel centrifugation assay (see Discussion). As acceptance criteria, we defined 100% concordance with peripheral blood data for ABD; for all other Ags, we required 0% false-positive results, but accepted a 10% false-negative rate. Occasional non-detection of some minor blood group Ags was expected, because some of the products had a hematocrit o1%, to yield very faint reactions. Descriptive statistics were calculated with Excel (Microsoft, Redmond, WA, USA).
Results
Lateral flow card assays
Initially, analysis of undiluted sample was attempted. The approach failed because of high leukocyte concentrations, which did not migrate into the lateral flow card. Dilutions of 1:3 (one drop of apheresis product and two drops of Diluent F) diffused into the lateral flow plate, but readings were too weak to generate reliable readings for Rh subtypes. A, B and D were always successfully detected, without any false-positive or false-negative results.
As ABD is not strongly discriminating, we sought to adapt the protocol to additionally detect Rh subgroups and K, and devised protocols for erythrocyte enrichment and leukocyte depletion. Various techniques were tested, Apheresis product ID by extended blood typing C Cummerow et al including simple centrifugation and aspiration of the erythrocyte pellet, hydroxy-ethyl starch sedimentation, Ficoll density centrifugation and immunomagnetic CD45 þ cell depletion. While with the exception of hydroxy-ethyl starch sedimentation all methods were successful and resulted in clearly interpretable test results from at least 10 samples for each method (CD45 þ cell depletion: n ¼ 4), the more complicated pre-analytic manipulation techniques provided no advantage over centrifugation, and were therefore not further pursued (data not shown). Using the above-described simple sample manipulation (centrifugation) and test protocol adapted to phenotyping of donor erythrocytes in the erythrocyte pellet of stem cell apheresis samples, 100 random apheresis samples were analyzed with lateral flow gel cards. Of these, 52 expressed the Ag A, 19 B, 86 D, 61 C, 81 c, 36 E, 96 e and 7 K, thus blood types were expressed with the expected frequency for the donor population. All tests yielded formally evaluable results, that is, negative and positive control spots performed as expected. All Ags were correctly identified with the exception of two 'small e' in heterozygote individuals, which were missed; in both apheresis products, although overall relatively weakly positive, the other Ags were correctly identified. Thus, the false-negative rate was 2% for 'e', 0% for all other Ags, and the false-positive rate was zero. The pre-defined acceptance rate was thus met.
Gel agglutination assays and conventional test tube assays
Alternative methods for blood typing, that is, gel centrifugation cards from DiaMed and Diagnostic Grifols, as well as tube tests with commercial sera (Biotest, Dreieich, Germany) were also tried. As in the gel centrifugation assay on top of all gel columns, including negative controls, leukocyte cell pellets were suspended, the assays were formally invalid. With adapted algorithms for analysis, however, blood group testing of apheresis products with gel centrifugation cards was also feasible with all the various sample preparation techniques. With instructions, this method would thus also be useful for blood typing of apheresis samples. However, the assay takes a little longer (12 min), requires a specific gel card centrifuge and some immunohematology experience. For these reasons, the gel card test was considered the less preferred method, and only 23 samples in total were analyzed. Using the described 'modified' approach to gel card analysis, 100% of all Ags were correctly identified, 0% were missed and 0% false positives were called.
To perform 10 test tube assays (A, B, D, C, c, E, e, K, positive and negative control), either unmanipulated apheresis products or erythrocyte sediment re-suspended in 1 mL of saline were used. One drop each of sheer apheresis product or erythrocyte suspension was mixed with one drop of specific antiserum. Tubes were briefly centrifuged, then tapped lightly to disperse the erythrocyte pellet without destroying erythrocyte agglutinates. Resulting agglutinates were weak, so that readings, except in most cases for A, B and D, were somewhat arbitrary, but to an experienced immunohematology technician overall feasible. To a transplant physician with limited immunohematology experience, the tube test method would not be recommended.
Discussion
Compared with the IT-supported production and labeling of conventional blood products, those safety standards applied to stem cell products are generally rather low. Moreover, stem cell products are generated by a multitude of facilities all over the world, most of them outside of the jurisdiction and control of the transplant facility. Common safety standards cannot be assumed, nor is it practicable for the transplant center to individually ascertain adherence to standards in each of the contracting apheresis centers. (a) Lateral flow assay: assays were performed as described. Red bands are indicative of erythrocytes retained by the immobilized Ab. In this representative example, the blood group thus reads as A Rh þ CcD.ee, K þ . (b) Gel centrifugation assay: assays were performed as described. After centrifugation, if faint erythrocyte pellets are found at the bottom of the gel column, this indicates the absence of the respective Ag on the cells, that is, the sample lacks A, B, E and K (small arrows). Accordingly, the blood type reads O Rh þ CcD.ee, KÀ. The bold arrows indicate the leukocyte-rich pellet on top of the negative control gel columns (also observed on top of all other gel columns), which was observed with all apheresis products, renders the test formally invalid, and required development of the described alternative algorithm for assay analysis when used with stem cell products.
Transfusion of a stem cell product to a non-intended recipient has not been reported in the literature, but the frequency of human error in all other fields of medicine would suggest that it may have occurred at some point. By extrapolation from other blood products, the risk of a patient receiving the wrong transplant could be considerable: mislabeling of 0.4% of cord blood units received for transplantation was recently reported from one of the largest cord blood transplant programs. 4 The risk of infusing 'wrong' red cell concentrates in the United Kingdom was estimated as 41:10 000, 1000-fold higher than the combined risk of contracting Hepatitis B, Hepatitis C or HIV from a blood product, and deaths attributable to infusion of 'wrong' blood occur every year. 3 We therefore feel that introduction of minimal product identification, based on a reasonably well-discriminating biological marker in the stem cell product itself, as an additional layer of confirming product (or donor) identity will add to the safety of transplant recipients.
The manuscript describes simple protocols, to be performed on a sample of the apheresis product recovered from a tube segment or from a quality control sample drawn in the transplant center, that is, without compromising the integrity of the product itself but guaranteed to be representative of its contents, which allow stem cell product identification by extended blood typing of the stem cell apheresis product. The degree of discrimination depends on the donor's blood type (see Table 2 ). The frequencies of the two most common blood types in Caucasians, O Rh þ CcD.ee Cw-K-and A Rh þ CcD.ee Cw-K-, are each less than 1:7 (see Table 2 ). 7 For products from such donors, the degree of discrimination is increased 2.5-fold over analysis of ABD alone. Thus, 37% of the Caucasian population are A þ , but only 40% of these (15%) have the abovementioned phenotype A þ CcD.ee. Other Rh phenotypes, however, are virtually unique and thus highly discriminating (see Table 2 ). In consideration of their frequencies in the population, presence of the K Ag increases resolution by a factor of 10, presence of Cw in a big-C positive individual by another factor of 50, presence of both by a factor of 500 and so on. Therefore, there should be considerable value in performing the test. At o0.1% of the cost of a stem cell product, the price of the test is nominal.
As we showed, a number of erythrocyte enrichment techniques and at least two common blood typing assays can be used for apheresis product identification in this fashion. Because of the simplicity of the protocol, the long shelf life of the reagents and the fact that specific laboratory instruments are not required, centrifugation combined with the lateral flow assay was selected as the preferred method, which was formally validated on a larger sample size. Similar assays might also be desirable for other stem cell sources. For blood group analysis of BM samples, modified protocols are not required; they can be analyzed with all available blood typing technologies, including the lateral flow card, by following the protocols for peripheral blood (not shown). Frozen samples cannot be analyzed in this fashion because of untoward freeze-thaw properties of erythrocytes. However, analyses of frozen samples are likely less time-critical; a tube segment can be subjected to confirmatory HLA typing before the patient conditioning is started.
How should the assay be used? We would recommend for transplant centers to perform an extended blood typing assay on all allogeneic stem cell products, using one of the described protocols, and then compare the result with the 'expected' blood group according to the donor clearance form, as well as with the donor and recipient information printed on the label and product information. Any discrepancy should result in delay of the transplantation and instantaneous PCR-based typing for HLA class I. Immediate contact with the apheresis center should also be sought, as very likely the counterpart to the wrongly dispensed product will have been carried to a different transplant center, putting the life of a second recipient at risk. The tests cannot substitute for utmost scrutiny in ascertaining donor identity and proper labeling in the apheresis center, nor in cross-checking accompanying documents for correct donor/recipient identity in the transplant center.
In summary, we are presenting a validated protocol for stem cell apheresis product identification, based on extended blood group Ag testing on apheresis products. Introduction of this or similar tests into 'best practice' algorithms can further reduce the risk of a product mix-up, that is, the definitively lethal transplantation of a stem cell product from the wrong donor. 8, 9 Conflict of interest PS and MS are employees of Medion Grifols Diagnostics, a product of which was used for these studies. None of the other authors have a potential conflict of interest to declare. Apheresis product ID by extended blood typing C Cummerow et al
